NCT06847867View on ClinicalTrials.gov

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

June 3, 2027

Study Completion Date

March 6, 2029

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Momelotinib

Momelotinib will be administered.

Trial Locations (1)

44718

RECRUITING

GSK Investigational Site, Canton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06847867 - A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter